Fresenius SE & Co. KGaA (0OO9.L)
- Previous Close
26.93 - Open
26.93 - Bid --
- Ask --
- Day's Range
26.93 - 27.18 - 52 Week Range
19.69 - 44.62 - Volume
16,220 - Avg. Volume
524,922 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
www.fresenius.com175,202
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0OO9.L
View MorePerformance Overview: 0OO9.L
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0OO9.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0OO9.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
1.91%
Return on Assets (ttm)
2.68%
Return on Equity (ttm)
5.06%
Revenue (ttm)
22.13B
Net Income Avi to Common (ttm)
1.2B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
2.39B
Total Debt/Equity (mrq)
67.91%
Levered Free Cash Flow (ttm)
1.48B